AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06049862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MaRiTensi App
Description: MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat.
Study NCT04632810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic low energy diet
Description: Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks
Study NCT04632810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-ketogenic low energy diet
Description: Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
Study NCT04449991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeat kidney biopsy
Description: Intensification of immunosuppression if NIH AI > 3
Study NCT06084234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GALAD
Description: GALAD is a 3 biomarker panel incorporating AFP, AFP-L3% and DCP (all FDA approved), with patient age and sex.
Study NCT06084234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Liver Ultrasound with or without AFP
Description: This intervention consists of current standard of care ultrasound based surveillance with or without alpha-fetoprotein measurement.
Study NCT05492344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized ventilation
Description: Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver
Study NCT05492344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg
Study NCT04904328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumishade® Active Lens
Description: Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)
Study NCT04904328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lumishade® Sham Lens
Description: Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)
Study NCT06197750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Description: Vestibular stimulation by swing
Study NCT06197750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General strengthening exercises
Description: General strengthening exercises
Study NCT05881915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
Study NCT05881915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
Study NCT05845008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium Fixed Combination
Description: Acetaminophen/naproxen sodium fixed combination tablets, oral.
Study NCT06301594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic simple swallowing training
Description: Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week
Study NCT05499598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C
Description: Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
Study NCT05499598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified minimally invasive surgical technique with PRF
Description: Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
Study NCT05526781 — intervention group
Intervention type: DEVICE
Intervention: Clareon monofocal Intraocular lens (toric and non-toric models)
Description: Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
Study NCT06137144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3470
Description: AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
Study NCT05444751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthetic
Description: Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence.
Study NCT05444751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA + ESP
Description: The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation.
Study NCT05796349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multifrequency EIT-based for detecting intracranial abnormalities
Description: For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
Study NCT05308667 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation (modified constraint-induced movement therapy)
Description: Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
Study NCT05308667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation (modified constraint-induced movement therapy)
Description: Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
Study NCT05308667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation (modified constraint-induced movement therapy)
Description: Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
Study NCT05308667 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-invasive brain stimulation (intermittent theta-burst stimulation)
Description: Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
Study NCT05308667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-invasive brain stimulation (intermittent theta-burst stimulation)
Description: Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
Study NCT04961827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-efficacy based images through instant messaging
Description: A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
Study NCT04961827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge based images through instant messaging
Description: A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
Study NCT05645653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational tteaching
Description: A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
Study NCT06306352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback
Description: The ABLE exoskeleton is accompanied by a vibrotactile feedback belt which users wear around their chest to receive real-time feedback during the double support phase. This feedback can assist them in their weight shift during the double support phase.
Study NCT05967208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONSORT referrals
Description: Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts.
Study NCT05967208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Card referrals
Description: Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts.
Study NCT05967208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Card referrals
Description: Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts.
Study NCT06403189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biologic samples and MRI
Description: * blood sample~* lumbar punction~* MRI
Study NCT05435547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Will take Dexamethasone pre-operatively
Study NCT05435547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will take Placebo pre-operatively
Study NCT05895838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
Study NCT05895838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
Study NCT05895838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Backrest elevation
Description: Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
Study NCT05895838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Backrest elevation
Description: Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
Study NCT05895838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early wakeup call
Description: Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
Study NCT05895838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early wakeup call
Description: Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
Study NCT05895838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
Study NCT05895838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
Study NCT05847504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mSTARS
Description: mSTARS combines inpatient cognitive-behavioral skills training and outpatient use of a mobile app encouraging application of acquired skills to real life situations.
Study NCT05932862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL309 (ISM3091)
Description: XL309 will be administered orally once daily.
Study NCT05932862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib administered orally twice daily.
Study NCT04854772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Body Syndrome Therapy for Long Covid
Description: The intervention consists of a mind-body based intervention for the COVID long haul syndrome. The components of the intervention include knowledge therapy, desensitization, emotional expression, and stress reduction techniques.
Study NCT05888805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DIMS spectacle lens
Description: DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
Study NCT04505358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Description: active vs placebo
Study NCT04505358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: active vs placebo
Study NCT04853199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Each patient should receive one tablet twice a day 30 minutes before the meal
Study NCT04853199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
Study NCT05447871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided single injection modified 4 in 1 block technique
Description: A high-frequency ultrasound probe is placed over the femoral condyle and vastus medialis muscle is identified. The probe is slid proximally till the superficial femoral artery appeared. The probe is slid proximally till the descending genicular artery branching from the superficial femoral artery. The point of interest is 8-10 cm above the femoral condyle. The needle is guided into the Vastus medialis muscle till the nerve to Vastus medialis. At this point, 5-7 mL of the local anaesthetic drug is injected. The needle is guided further in-plane from lateral to medial side to reach the perivascular region and after negative aspiration 25 ml local anaesthetic drug is injected.
Study NCT05447871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided adductor canal block technique
Description: The Adductor canal is identified in the middle of the thigh beneath the sartorius muscle using a high-frequency ultrasonic transducer. the probe is slid till the superficial femoral artery appeared in the adductor canal between vastus medialis and adductor longus muscle. A 22-gauge spinal needle is inserted in a lateral to medial plane to reach the perivascular region and after negative aspiration 20 ml local anaesthetic drug is injected, visualised to push the femoral artery.
Study NCT05447871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: bupivacaine 0.25%
Study NCT05447871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: bupivacaine 0.25%
Study NCT05826860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Practice
Description: Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
Study NCT05826860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Workshop
Description: Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
Study NCT04843475 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Trans-thoracic Echocardiography
Study NCT02847013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP block w Liposomal bupivacaine
Description: TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
Study NCT02847013 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block w normal saline
Description: TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
Study NCT06008743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belt Accelerations
Description: Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control. The speed of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg.
Study NCT06008743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belt accelerations combined with an exoskeleton
Description: Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with independent speed control, and using a hip exoskeleton. The velocity of each belt will increase with constant acceleration during double support, shortly before push-off of the supported leg. At the same time, they will be interacting with a wearable motion assistive device (i.e., exoskeleton). The exoskeleton will apply forces to the leg to resist hip extension during accelerations, reducing hip extension relative to the values of that participant at baseline.
Study NCT06008743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable Stiffness treadmill
Description: Intervention used in both healthy and stroke survivors. In this mode, participants are walking on a treadmill with two belts with identical speed control. A variable stiffness mechanism under one belt will change the vertical stiffness of one side of the treadmill for one or multiple steps. The walkers will be informed before stepping on the softer surface on one side, which can be either the left or the right side.